Understanding how disruptions in cell cycle regulation can lead to cancer
Official title: Mechanisms of tumor initiation upon disruption of the Rb/E2f interaction
Funded at Lankenau Institute for Medical Research · NIH-10854953 · Data updated 2026-11-12
This study is looking at how certain proteins in our cells work together and how their loss might lead to liver cancer, hoping to find new ways to treat it and help patients understand what causes this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lankenau Institute for Medical Research NIH-funded |
| Lab location | 1 site (Wynnewood, United States) |
| Project start | April 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $361,475 |
| NIH project number | 5R01CA251397-05 |
| Project ID | NIH-10854953 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk for hepatocellular carcinoma or those with early-stage liver cancer.
✕Less likely to help
Patients with cancers unrelated to the Rb/E2f pathway or those with advanced liver cancer may not benefit from this research.
What this research studies
This research investigates the role of E2f transcription factors and their interaction with Rb family proteins in the initiation of tumors, particularly focusing on hepatocellular carcinoma (HCC). The study aims to uncover how the loss of this interaction contributes to cancer development and whether the differentiation status of cells influences this process. By using a model that mimics human HCC, the research seeks to fill gaps in our understanding of cancer biology and identify potential therapeutic targets. Patients may benefit from insights gained into the mechanisms of tumor initiation and progression.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating liver cancer.
How similar studies have gone: Previous research has shown that targeting cell cycle regulation can be effective in cancer treatment, suggesting potential for success in this area as well.
Where this research is happening
-
Lankenau Institute for Medical Research
Wynnewood, United States Active
Researchers
- Principal investigator: Viatour, Patrick — Lankenau Institute for Medical Research
- Study coordinator: Viatour, Patrick
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.